News and Trends 18 Feb 2021 Cannabinoids in Focus after GW Pharmaceuticals Snapped up for €6B This month’s €6B acquisition of the UK heavyweight GW Pharmaceuticals by Jazz Pharmaceuticals has been hailed as a major validation of the medical cannabinoid industry. The deal is the largest to date in the medical cannabinoid field. Jazz’s offer valued GW’s shares nearly 50% higher than their previous day’s close. The acquisition is expected to […] February 18, 2021 - 6 minutesmins - By Victor Kotsev Share WhatsApp Twitter Linkedin Email
News and Trends 26 Jun 2020 UK Loosens Controls on GW’s Cannabinoid Epilepsy Drug A cannabinoid medication marketed by GW Pharmaceuticals for the treatment of severe forms of epilepsy will be more easily available to patients in the UK after the drug was moved to the least strict classification by the country’s Home Office. The medication — branded as Epidyolex in the EU and Epidiolex in the US — […] June 26, 2020 - 4 minutesmins - By Victor Kotsev Share WhatsApp Twitter Linkedin Email
More News! 8 Oct 2018 Cannabinoid Drugs Company Raises $300M in Public Offering GW Pharmaceuticals, a British biotech developing cannabinoid drugs, is on a high after a successful $300M public offering on the Nasdaq Stock Market. The company announced the public offering swiftly after its lead cannabinoid drug, Epidiolex, made history by being the first cannabinoid drug to obtain approval from the FDA earlier this year. GW plans […] October 8, 2018 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 26 Jun 2018 Update: The FDA Approves First Cannabinoid Treatment for Epilepsy Update (26/06/2018): The FDA has approved GW Pharmaceutical’s drug Epidiolex in two severe forms of epilepsy. The approval makes Epidolex the first prescription drug made from highly purified cannabidiol to reach the market. Published on 20/04/2018 GW Pharmaceuticals has received a unanimous recommendation from the FDA Advisory Committee Meeting supporting the approval of what could soon […] June 26, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 22 Feb 2018 GW Pharma’s Latest Cannabinoid Drug Pegged Back by a Placebo in Phase II One of GW Pharma’s cannabinoid drugs for epilepsy has suffered a set back in a Phase IIa trial as a placebo matched its capacity to reduce the frequency of focal seizures. GW Pharma wants to use cannabinoid drugs to treat conditions like autism and epilepsy. However, one of its drug candidates, GWP42006, has slipped up in a Phase […] February 22, 2018 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 25 Jan 2018 Yet More Good News for GW Pharma’s Cannabinoid Drug Against Epilepsy New data in The Lancet provides further support for GW Pharma’s drug, Epidiolex, for the treatment of a rare form of epilepsy. GW Pharmaceuticals has achieved encouraging Phase III results for Epidiolex, which have been published in leading scientific journal, The Lancet. The company’s lead candidate is being developed for the treatment of epilepsy – a […] January 25, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
Best in Biotech 18 Dec 2017 Smile! Here are the 12 Biggest Biotech Clinical Successes of 2017 Now that we’ve got the bad news out of the way, we’re here to spread some Christmas cheer with the biggest clinical successes in biotech over the past 12 months. It’s unlikely that one whole year will ever pass without a single hiccup, especially in a field as complex as biotech. For that reason, we […] December 18, 2017 - 9 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 15 Dec 2017 Signed, Sealed. Will GW Pharma’s Epilepsy Treatment Be a 2018 Blockbuster? GW Pharma might be about to join the likes of Genmab in the biotech blockbuster club, with its epilepsy drug predicted to achieve sales of close to $1B in 2018. GW Pharma develops therapies for a range of diseases, including autism, epilepsy and brain cancer using its cannabinoid product platform. In a rundown of the top 10 […] December 15, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
More News! 9 Aug 2017 UK Cannabinoid Company Loses 9% and a Competitor after American Phase II Failure Zynerba Pharmaceuticals cannabinoid drug for epilepsy missed all of its endpoints costing the company’s stock price more than 55% — and GW Pharma 8.6%. On Monday, Zynerba Pharmaceuticals, a Pennsylvania-based biotech, announced that its transdermal cannabinoid candidate ZYN002 for refractory epilepsy with focal seizures had not met any of its endpoints in a Phase II […] August 9, 2017 - 2 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
More News! 29 Mar 2017 More “FDA Love” for Cannabis Company with Orphan Drug Designation Last year was a doozy for biotech, but it was spectacular for GW Pharmaceuticals. Its streak continues with more special treatment. GW Pharmaceuticals, which is developing epilepsy treatments from marijuana, is making a name for itself not just as “that company” turning a recreational drug into medical ones; the company was also one of 2016’s surprise successes — its […] March 29, 2017 - 2 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 7 Feb 2017 Cannabinoid Drug Prolongs the Life of Brain Tumor Patients in Phase II Trials GW Pharmaceuticals announced Phase II results for a cannabinoid drug combination with the potential to increase life expectancy in patients with an aggressive form of brain cancer. GW Pharmaceuticals, one of the coolest biotechs in Cambridge, is developing cannabinoid drugs. Its lead candidate, Epidiolex, could reach the market soon and help treat drug-resistant forms of […] February 7, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Best in Biotech 30 Jan 2017 The Shiniest Golden Vertex? 15 Great Biotechs in Cambridge Cambridge’s image is tied to its Hogwarts-like University and Nobel-hoarding academia, but there’s also an exciting entrepreneurial scene at the cutting edge of technology. We took a look at how big biotech is in the Silicon Fen. Cambridge’s Biotech cluster has an exemplary hive of talent, infrastructure, and capital – enough to create the same vibe […] January 30, 2017 - 8 minutesmins - By Denise Neves Gameiro Share WhatsApp Twitter Linkedin Email